Amy Charlotte Foulkes

Amy Charlotte Foulkes
The University of Manchester · Institute of Inflammation and Repair

BMedSci (Hons) BMBS PhD MRCP (Derm)

About

34
Publications
2,829
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
360
Citations
Introduction
Academic Clinical Lecturer in Dermatology
Additional affiliations
January 2011 - present
The University of Manchester
Description
  • North West England MRC Clinical Research Training Fellow in Clinical Pharmacology and Therapeutics
January 2011 - April 2016
The University of Manchester
Position
  • North West England MRC Clinical Research Training Fellow in Clinical Pharmacology and Therapeutics
Education
September 1999 - August 2004

Publications

Publications (34)
Article
Introduction and aims Biologics targeting the tumour necrosis factor (TNF) and the interleukin (IL)-17/23 axis are highly effective treatments for psoriasis but can result in cutaneous adverse events. The pathogenesis of paradoxical eczema, an atopic dermatitis (AD) phenotype occurring after biologic initiation in people with psoriasis, is unknown....
Article
Importance Biologics used for plaque psoriasis have been reported to be associated with an atopic dermatitis (AD) phenotype, or paradoxical eczema, in some patients. The risk factors for this are unknown. Objective To explore risk of paradoxical eczema by biologic class and identify factors associated with paradoxical eczema. Design, Setting, and...
Article
Background: Few studies have explored the immunology and genetic risk of paradoxical eczema occurring as an adverse event of biologic therapy in patients with psoriasis. Objectives: To describe the systemic inflammatory signature of paradoxical eczema using proteomics and explore if this is genetically mediated. Methods: We used the Olink Targ...
Article
Few studies have explored the immunology and genetic risk of paradoxical eczema occurring in patients with psoriasis treated with biologics. This study aims to describe the systemic inflammatory signature of paradoxical eczema using proteomics and explore whether it is genetically mediated. Participants were adults treated with biologics for plaque...
Article
The multidisciplinary team (MDT) model has been previously demonstrated to improve early diagnosis and outcomes for psoriatic arthritis [Zheng YX, Zheng M. A multidisciplinary team for the diagnosis and management of psoriatic arthritis. Chin Med J (Engl) 2021; 134:1387–9; Luelomo J, Gratacós J, Martínez-Losa MM et al. A report of 4 years of experi...
Article
Biologic therapies for psoriasis can cause paradoxical eczema. The role of genetic factors in its pathogenesis are unknown. To identify risk variants, we conducted a genome-wide association study (GWAS) of 3212 psoriasis patients, of whom 88 developed paradoxical eczema. Two lead single nucleotide polymorphisms (SNPs) reached genome-wide significan...
Article
Full-text available
Background Biologic and non-biologic immunomodulators, used to treat immune-mediated inflammatory diseases (IMID), could impair the immune response to COVID-19 vaccines and therefore vaccine effectiveness. Objectives Our objective was to investigate the association between biologic and non-biologic immunomodulators and seroconversion following the...
Article
Full-text available
Atopic eczema and psoriasis are chronic, inflammatory dermatoses that can significantly affect the quality of life of those affected. Although both diseases are common, they rarely occur together. Severe psoriasis can be treated with biologic therapies targeting specific cytokine pathways involved in disease pathogenesis. There are reports of parad...
Article
The use of biologic therapies for the treatment of chronic plaque psoriasis has been linked to the development of atopic eczema, amongst other cutaneous adverse events. This can cause diagnostic confusion and create difficulty in the management of patients with plaque psoriasis. The main objective of this systematic review was to review all cases o...
Article
Full-text available
Brodalumab is a recombinant, fully human monoclonal antibody (IgG2) which binds with high affinity to the interleukin (IL) 17 receptor A (IL17R). Brodalumab is now licensed and approved for the treatment of moderate-to-severe chronic plaque psoriasis in North America and Europe. As the third to market in the class of agents targeting IL-17, we revi...
Article
Full-text available
Biologic therapies have shown high efficacy in psoriasis, but individual response varies and is poorly understood. To inform biomarker discovery in the Psoriasis Stratification to Optimise Relevant Therapy (PSORT) study, we evaluated a comprehensive array of omics platforms across three time-points and multiple tissues in a pilot investigation of t...
Article
This review provides a summary of key findings from 27 systematic reviews of 51 articles first published or indexed during 2015, focusing on the treatment of psoriasis as well as precision medicine in psoriasis. Evidence supports weight loss interventions by dieting and exercise for the improvement in disease severity in overweight and obese patien...
Article
The era of high throughput sequencing (HTS; otherwise known as next-generation sequencing) has revolutionised dermatological research. New publications describing successful translational research based on interpretation of omics data from dermatological sources appear each month. Bioinformatics refers to the tools used to collect, classify and ana...
Article
High-throughput biology presents unique opportunities and challenges for dermatological research. Drawing on a small handful of exemplary studies, we review some of the major lessons of these new technologies. We caution against several common errors and introduce helpful statistical concepts that may be unfamiliar to researchers without experience...
Article
Linked Article: Talamonti et al. Br J Dermatol 2017; 177:489–496.
Article
Psoriasis is a model disease for the development of pharmacogenomic markers of treatment response, with ready access to diseased tissue and objective validated outcome measures. With the application of state-of-the-art technologies and investment in careful experimental design, the goal of stratified medicine in psoriasis may be possible. Current p...
Article
Full-text available
Methotrexate continues to be one of the most widely used systemic immunosuppressive agents in dermatology. In addition to the important, well-characterized adverse effects such as hepatotoxicity and myelosuppression, methotrexate may induce a number of rare cutaneous adverse events including methotrexate-induced ulceration. We present a case of met...
Article
A 49-year-old Caucasian male was referred to the Manchester Psoriasis Service with a 21-year history of severe chronic plaque psoriasis refractory to therapy with topical agents, phototherapy (TL-01), systemic agents (methotrexate, ciclosporin and fumaderm) and the biologic agents adalimumab and ustekinumab, including with concurrent ciclosporin th...
Article
Patients who suffer from inflammatory skin disease are at risk of stigmatisation and physical and psychological co-morbidities. To an extent these issues can be offset by effective coping strategies. The cumulative balance of these interactions will often lead to impairment, especially in those whose coping mechanisms are maladaptive or do not exis...
Article
Although catastrophic vascular complications in vascular Ehlers-Danlos Syndrome (EDS) are well recognized, other complications such as flexion contractures and tendon nodules are rarely reported and poorly characterized. We report a young man with vascular EDS, who developed flexion contractures and tendon nodules, causing considerable disability....
Article
Psoriatic arthritis remains a common cause of morbidity in patients with psoriasis. Little is known about the natural history of the disease and dermatologists do not consistently screen for its presence. We describe a patient with severe psoriasis where long-term biologic therapy with a tumour necrosis factor inhibitor was interrupted for clinical...
Article
This review summarizes key clinical findings from 5 guidelines and 21 systematic reviews on psoriasis published or indexed in the period November 2009 to October 2010. The highlights include the British Association of Dermatologists guidelines on the use of biological interventions in psoriasis, and guidelines on the efficacy and use of acitretin....
Article
We report three cases of thyrotoxicosis who presented acutely with headache to our neurology service in a 1-year period. In two of these patients there was a pre-existing or subsequent history of migraine. With hindsight, there were other clinical features of thyrotoxicosis but this diagnosis had been missed in primary care. Severe headache can be...

Network

Cited By